Felix Lourdes 4

What Happened
Felix Lourdes, a director of Lixte Biotechnology Holdings, received a grant of 30,000 restricted share units (RSUs) reported on July 1, 2026. The RSUs were awarded at $0.00 (no cash paid) and vested upon satisfaction of the applicable performance conditions. Each RSU represents a contingent right to receive one share of common stock upon vesting.

Key Details

• Transaction date and type: 2026-07-01 — Grant/Award (Code A) of 30,000 RSUs at $0.00 per RSU.
• Ownership reporting: the filing notes the total reported includes the 30,000 newly awarded RSUs plus 25,000 RSUs (all of which have vested), i.e., 55,000 RSUs referenced in the report.
• Filing timeliness: Form 4 was filed 2026-07-02 for a 2026-07-01 transaction (timely under Form 4 rules).
• Footnotes: (F1) RSUs granted under the 2020 Stock Incentive Plan; vested upon satisfaction of performance conditions. (F2) Column 5 totals include both the new 30,000 RSUs and 25,000 RSUs previously awarded.

Context
RSUs are a form of equity compensation, not an open-market purchase or sale. They create a contingent right to receive shares (and may dilute current holders when settled) and are typically granted to align insider incentives with company performance. Receipt of RSUs is routine compensation-related activity and does not, by itself, indicate insider buying or selling sentiment.